MISSISSAUGA, Ontario--(EON: Enhanced Online News)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that a clinical case series demonstrating the clinical effectiveness of ColActive® Plus and ColActive Plus Ag biological matrix dressings will be presented at the 2017 Symposium on Advanced Wound Care Spring (“SAWC Spring”) in San Diego, California by Dr. Afsaneh Alavi, MD, MSc, FRCPC. Covalon will also be presenting its full line of advanced wound care products in the symposium’s exhibition hall, during the three-day event.
“Our findings in this case series suggests that chronic wounds in patients that received collagen matrix dressings were markedly improved over an 8-week period, where 8 out of 9 patients showed significant improvements”
“We are excited to have Dr. Alavi share with her peers at SAWC the clinical evidence from her experience using ColActive Plus on a series of patients,” said John R. Hands, Executive Vice President of Marketing at Covalon Technologies Ltd. “The wounds chosen by Dr. Alavi for this study are some of the most difficult chronic wounds to close using standard courses of care.”
Dr. Afsaneh Alavi, MD, MSc, FRCPC and her team, who are associated with the University of Toronto, Faculty of Medicine, Division of Dermatology and the York Dermatology Centre, Richmond Hill, Ontario Canada will present a clinical poster entitled A Case Series to evaluate the clinical effectiveness of a Collagen Matrix wound dressing with or without silver during the SAWC Spring-WHS Poster Gala, held on Friday, April 7, 2017 from 7:15 p.m.–8:45 p.m.
“Our findings in this case series suggests that chronic wounds in patients that received collagen matrix dressings were markedly improved over an 8-week period, where 8 out of 9 patients showed significant improvements,” said Dr. Alavi. “We found that collagen matrix dressings like ColActive Plus may be more effective than standard care for chronic wounds.”
SAWC is the Official Meeting for Members of The Association for the Advancement of Wound Care and the leading national wound healing conference SAWC Spring serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research findings. The conference runs from April 5-9, 2017, and Covalon will be exhibiting in booth #128 during all exhibit hours throughout the meeting.
Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician. Covalon’s CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound closure and healing in both acute and chronic wounds.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.